dazodalibep   Click here for help

GtoPdb Ligand ID: 13453

Synonyms: MEDI-4920 | MEDI4920 | VIB 4920 | VIB-4920 | VIB4920
Immunopharmacology Ligand
Compound class: Peptide
Comment: Dazodalibep (VIB4920, formerly MEDI4920) is a fusion protein that is designed to bind to and neutralise the biological actions of the CD40 ligand (CD40L) [1-2]. Structurally dazodalibep contains two tandem human Tn3 tenascin C modules (that bind CD40L [3]) linked to human serum albumin. Previous studies have demonstrated that anti-CD40L antibodies can cause thromboembolic adverse events that arise through antibody Fc-mediated cross-linking between FcγRIIa and CD40L on platelets. The dazodalibep Fc negative fusion protein approach was initiated to mitigate these platelet-related safety issues.
No information available.
Summary of Clinical Use Click here for help
Dazodalibep (VIB4920) is being developed as an novel immunomodulator for the treatment of autoimmune diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04163991 A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis Phase 2 Interventional Viela Bio (acquired by Horizon Therapeutics)
NCT06104124 A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity Phase 3 Interventional Amgen
NCT06245408 A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State Phase 3 Interventional Amgen
NCT04129164 A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome Phase 2 Interventional Amgen 4